Clear All
777 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9356 Trastuzumab and Hyaluronidase-oysk Herceptin hylecta 10mg Immunotherapy Monoclonal Antibody HER2 No 2019 Jul 1, 2019 In Use
C9476 Daratumumab Darzalex 10 mg Immunotherapy Monoclonal Antibody CD38 No 2015 Jul 1, 2016 In Use
Q2057 Afamitresgene autoleucel Tecelra per therapeutic dose Immunotherapy T Cell Receptor (TCR) MAGE-A4 No 2024 Mar 26, 2025 In Use
J9144 Daratumumab, hyaluronidase-fihj Darzalex Faspro 10mg Immunotherapy Monoclonal Antibody CD38 No 2020 Jan 1, 2021 In Use
C9477 Elotuzumab Empliciti 1 mg Immunotherapy Monoclonal Antibody SLAMF7 No 2015 Jul 1, 2016 Dec 31, 2016 No Longer Used
J3263 Toripalimab-tpzi Loqtorzi 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2023 Jun 10, 2024 In Use
J9145 Daratumumab Darzalex 10 mg Immunotherapy Monoclonal Antibody CD38 No 2015 Jan 1, 2017 In Use
J1323 Elranatamab-bcmm Elranatamab-bcmm 1mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2023 Apr 17, 2024 In Use
C9491 Avelumab Bavencio 10 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2017 Oct 1, 2017 In Use
J9063 Mirvetuximab soravtansine Elahere 1mg Immunotherapy Drug Antibody Conjugate FR-alpha, DM4 No 2022 Jul 11, 2023 In Use
C9416 BCG BCG, Intravesical Per instillation Immunotherapy Biological Response Modifier Live Vaccine No 1990 Jan 1, 2004 Dec 31, 2003 No Longer Used
Adagrasib Krazati 200mg Immunotherapy RAS Inhibitor KrAS G12C Yes 2022 In Use
J9037 Belantamab mafodontin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 Apr 1, 2021 Mar 26, 2025 No Longer Used
C9110 Alemtuzumab Lemtrada 10 mg Immunotherapy Monoclonal Antibody CD52 No 2001 Jan 1, 2001 Dec 31, 2007 No Longer Used
C9082 Dostarlimab-gxly Jemperli 100mg Immunotherapy Checkpoint Inhibitor PD-1 No 2021 Sep 27, 2021 Jan 26, 2022 No Longer Used
J9275 Cosibelimab-ipdl UNLOXCYT 2mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2025 Jul 9, 2025 In Use
J9276 Zanidatamab-hrii ZIIHERA 2mg Immunotherapy Bispecific Antibody HER2 No 2024 Jul 9, 2025 In Use
NA Pomalidomide Pomalyst 4 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2013 In Use
C9174 Datopotamab Deruxtecan Datroway 1mg Immunotherapy Drug Antibody Conjugate Topoisomerase I No 2025 Jul 9, 2025 Sep 8, 2025 In Use
C9483 Atezolizumab Tecentriq 10 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2016 Oct 1, 2016 In Use
J9022 Atezolizumab Tecentriq 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2016 Jan 1, 2018 In Use
J9306 Pertuzumab Perjeta 1 mg Immunotherapy Monoclonal Antibody HER2 No 2012 Jan 1, 2014 In Use
C9148 Teclistamab-cqyv Tecvayli 0.5mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2022 Mar 17, 2023 Jul 11, 2023 No Longer Used
J9326 Telisotuzumab vedotin-tllv Emrelis 1mg Immunotherapy Drug Antibody Conjugate c-MET No 2025 Jan 12, 2026 In Use
J9302 Ofatumumab Arzerra 10mg Immunotherapy Monoclonal Antibody CD20 No 2009 Jan 1, 2011 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.